Drug reference

Amsacrine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1004, 1005

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Acute leukaemia (refractory to anthracycline chemotherapy used alone or in combination with other chemotherapy agents) (specialist use only) ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature)

PDF page 1004

Cautions

Hypokalaemia—increased risk of ventricular ﬁbrillation (correct hypokalaemia before initiating treatment)

PDF page 1004

Safety

Interactions

→Appendix 1: amsacrine

PDF page 1004

Side Effects

▶Common or very common Abdominal pain. alopecia. arrhythmias. bone marrow disorders. cardiotoxicity. congestive heart failure. diarrhoea. dyspnoea. emotional lability. fever. generalised tonic-clonic seizure. haemorrhage. hepatic disorders. hypokalaemia. hypotension. infection. nausea. necrosis. skin reactions. stomatitis. thrombocytopenia. vomiting ▶Rare or very rare Anaemia. cardiomyopathy. confusion. dizziness. granulocytopenia. headache. lethargy. leucopenia. numbness. peripheral neuropathy. proteinuria. renal impairment. visual impairment. weight changes ▶Frequency not known Cardiac arrest. hyperuricaemia

PDF page 1004

Conception And Contraception

Manufacturer advises effective contraception during and for 3 months after treatment in women of child-bearing potential, and during and for 6 months after treatment in men.

PDF page 1004

Pregnancy

Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 1004

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 1004

Hepatic Impairment

Manufacturer advises caution (increased risk of toxicity). Dose adjustments Manufacturer advises consider dose reduction (consult product literature).

PDF pages 1004, 1005

Renal Impairment

Manufacturer advises monitor renal function at baseline and during treatment—increased risk of toxicity. Dose adjustments Manufacturer advises consider dose reduction in renal impairment.

PDF page 1005

Monitoring Requirements

▶Manufacturer advises monitor full blood count, liver function and renal function regularly; electrolytes should be re-evaluated prior to each treatment. ▶Manufacturer advises monitor for cardiotoxicity during treatment.

PDF page 1005

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Solution for infusion ▶Amsidine (Eurocept International bv) Amsacrine 50 mg per 1 ml Amsidine 75mg/1.5ml solution for infusion ampoules and diluent | 6 ampoule P £1,200.00 (Hospital only)

PDF page 1005

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1004

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Amsacrine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1004, 1005

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 1004

Cautions

Hypokalaemia—increased risk of ventricular ﬁbrillation (correct hypokalaemia before initiating treatment)

PDF page 1004

Safety

Interactions

→Appendix 1: amsacrine

PDF page 1004

Side Effects

PDF page 1004

Conception And Contraception

Manufacturer advises effective contraception during and for 3 months after treatment in women of child-bearing potential, and during and for 6 months after treatment in men.

PDF page 1004

Pregnancy

Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 1004

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 1004

Hepatic Impairment

Manufacturer advises caution (increased risk of toxicity). Dose adjustments Manufacturer advises consider dose reduction (consult product literature).

PDF pages 1004, 1005

Renal Impairment

Manufacturer advises monitor renal function at baseline and during treatment—increased risk of toxicity. Dose adjustments Manufacturer advises consider dose reduction in renal impairment.

PDF page 1005

Monitoring Requirements

PDF page 1005

Dose and formulations

Medicinal Forms

PDF page 1005

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1004

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.